Genmab — Juni 2017
-
In addition, the FDA has granted a Standard Review period for the use of daratumumab in combination with pomalidomide and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received at least two prior therapies, with a proteasome inhibitor and an immunomodulatory agent. The PDUFA date for the combination of daratumumab with pomalidomide/dexamethasone is June 17, 2017.
-
Til os der ikke er helt skarpe på PDUFA: https://www.fool.com/knowledge-center/what-is-a-pdufa-date.aspx
-
Er denne kommenteret? http://www.medscape.com/viewarticle/881376 Måske Ofatumumab klarer sig bedre, men det må fase 3 jo vise.
-
Jan var ekstrem positiv omkring ofas muligheder i MS i går. Han gav udtryk får at ofa kunne være bedre end det tilsvarende medikament fra Roche. Roche er dog først mover. Så der har de en klar fordel.
-
Some education on PD-L1 , the 2nd little video is a must watch - really funny
https://medivizor.com/blog/2017/05/26/quick-guide-understanding-importance-fdas-keytruda-approval/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind